The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 05, 2018

Filed:

May. 28, 2014
Applicant:

Proclara Biosciences, Inc., Cambridge, MA (US);

Inventors:

Richard A. Fisher, Cambridge, MA (US);

Robert George Edward Holgate, Hertfordshire, GB;

Francis Joseph Carr, Aberdeen, GB;

Timothy David Jones, Cambridge, GB;

Assignee:

PROCLARA BIOSCIENCES, INC., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/00 (2006.01); C07K 2/00 (2006.01); C07K 5/00 (2006.01); C07K 7/00 (2006.01); C07K 4/00 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); C12N 7/00 (2006.01); C07K 14/73 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); C07K 14/70514 (2013.01); C12N 7/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C12N 2795/14122 (2013.01); C12N 2795/14133 (2013.01);
Abstract

The invention relates to polypeptides that comprise a portion of filamentous bacteriophage gene 3 protein (g3p) sufficient to bind to and/or disaggregate amyloid, e.g., the N1-N2 portion of g3p and mutants and fragments thereof, wherein that g3p amino acid sequence has been modified through amino acid substitution to be substantially less immunogenic than the corresponding wild-type g3p amino acid sequence when used in vivo. The polypeptides of the invention retain their ability bind to and/or disaggregate amyloid. The invention relates furthermore to the use of these variant g3p-polypeptides in the treatment and/or prevention of diseases associated with misfolding or aggregation of amyloid.


Find Patent Forward Citations

Loading…